Pharmaceutical Technology on MSN
Pfizer clinches $10bn Metsera deal as Novo Nordisk retreats
After mulling over competing offers from both Pfizer and Novo Nordisk, Metsera has decided to go with the former’s $10bn ...
Under the terms of the cash deal, Pfizer will pay $65.60 a share upfront and a contingent value right worth up to $20.65 a ...
In this week’s edition of InnovationRx, we look at the battle for Metsera, the departure of FDA’s top drug regulator, ...
Pfizer Inc. (NYSE:PFE) strengthens its global pharmaceutical leadership and research presence in the S&P 500 Index.
Pfizer on Tuesday raised its full-year profit forecast for the second quarter in a row as robust demand for its blockbuster ...
TipRanks on MSN
FDA approves generic version of Pfizer’s Premarin
The U.S. Department of Health and Human Services announced that the U.S. Food and Drug Administration is initiating the removal of broad “black ...
How many companies will be left standing once consolidation hits the AI in healthcare sector? Which pharma companies are ...
2don MSN
Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk
Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war against Novo Nordisk. Metsera, based in New York, is developing oral ...
Pfizer, we imagine, wasn't too happy about the shout-out its Viagra product got yesterday when International Criminal Court prosecutor Luis Moreno-Ocampo announced, as part of his investigation into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback